NSA 12/6/18 HOSPW Long Acting Injectable Buprenorphine

December 6, 2018

Speaker: Hisham Awadalla, PharmD, PGY1 Pharmacy Resident

Planner:  Janny P. Lee, PharmD

There is a need to understand this newer medication formulation for use in the United States for treating opioid use disorder.
Injectable Buprenorphine is intended for abdominal subcutaneous injection only by a healthcare provider. SUBLOCADE is available only through a restricted distribution program called the SUBLOCADE REMS Program because of the risk of serious harm or death that could result from intravenous self-administration.
While data has shown effectiveness of Injectable Buprenorphine in maintaining opioid abstinence, there is no head to head study between different formulations of Buprenorphine to prove its superiority over other formulations. Therefore based on clinical evidence, safety profile and cost of treatment, Injectable Buprenorphine is only recommended for a subset of population who fails the conventional treatment for opioid use disorder. Further research is needed to gain a better understanding of the motivations for and effects of injectable Buprenorphine.

The goal of this CME presentation is to enhance providers' knowledge of different treatment for opioid use disorder.  Also, there will be another focus to review the new formulation of buprenorphine by injection.  Based on current evidence presented, a treatment algorithm will be proposed to guide the treatment for opioid use disorder. The take home message is the long acting injectable buprenorphine should be reserved for a subset of population who fails all conventional treatment.

Treatment methods for Opioid Use Disorder by daily dosing strategies also have been associated liabilities such as under-treatment due to missed doses and public health concerns such as purposeful diversion and accidental poisoning, especially in young children.   In Georgia, 11.5% of IDUs reported that buprenorphine was their first drug of dependence.

According to a 2016 report by the CDC, there were approximately 46,000 opioid related overdose deaths in 2016. When the CDC further evaluated that data based on ethnicity, they found that nearly 80% of those deaths, more than 33,000 of those Americans were white non-hispanics. The CDC also found that of those 46,000 deaths, about 11,000 of them were contributed to prescription opioids. 

Kaiser Napa Solano Area is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians.  The Kaiser Napa Solano Area designates this Live Activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.​​​​​​​

​​​​​​​​​​​​​​

Target Audience

Primary care physicians and other interested clinicians

Learning Objectives

  • Describe the epidemiology and pathophysiology of opioid use disorder.
  • Identify mild, moderate and severe opioid use disorder using the DSM-V criteria.
  • Utilize the COWS assessment tool to assess a patient's opioid withdrawal.
  • Demonstrate an understanding of the available maintenance treatment options for opioid use disorder. 
  • Demonstrate an understanding of long acting injectable buprenorphine and its use.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
Course opens: 
12/06/2018
Course expires: 
12/06/2018
Event starts: 
12/06/2018 - 12:30pm
Event ends: 
12/06/2018 - 1:30pm
Rating: 
0

Kaiser Napa Solano Area is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians.  The Kaiser Napa Solano Area designates this Live Activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.​​​​​​​

​​​​​​​​​​​​​​

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™

Accreditation Period

Course opens: 
12/06/2018
Course expires: 
12/06/2018
Please login or register to take this course.